SBIR/STTR Research Award
Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD
Award amount
$378,485Program and phase
STTR · Phase IAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MASSACHUSETTS GENERAL HOSPITAL
- Proposal award date
- 2018-09-30
- Contract end date
- 2019-08-31
- UEI
- FLJ7DQKLL226
- Solicitation number
- PAS18-188
- Topic code
- NIA
Research abstract
Abstract
Overmillion Americans are currently affected by Alzheimerandapos s diseaseADwith an economic burden
estimated at andgt$billion year inthat is projected increase at least four fold over next several decadesIn spite of the dearth of pharmacological options to modify the course of the disease at presentthe field has
developed accurate biomarkers that demonstrate that the pathology of AD is presentyears of more prior to
the onset of memory symptomsThere is converging opinion at the national level and within pharmaceutical
companies that our best strategy to develop disease modifying therapies is to design clinical trials during this
asympomaticpreclinical periodThe accurate biomarkers that detect individuals in theyear preclinical
period of ADprior to the onset of memory symptomshave limitationsThey are largely radiological indicatorswhich are expensive and require the subject to travel to a remote locationMoreoverwith the advent of a
disease modifying therapeuticscreening themillion people above the age ofto determine who would
benefit from this therapy is prohibitively expensiveTo address this critical unmet medical needwe developed
an algorithm of olfactory tests that functionally probe two vulnerable neural circuits with early signs of
pathologyolfactory and memory circuitsIn clinically normal elderly individualswho have undergone
longitudinal neuropsychological testing and radiographic phenotypingthe Percepts of Odor Episodic MemoryPOEMalgorithm identified clinical normal individuals with selective odor memory deficitsnormalized to other
aspects of their individual olfactory functionodor discrimination and odor identificationThose clinically
normal elderly individuals with a selective odor memory deficit were enriched in thekey AD risk factorsApoEthe strongest genetic risk factor for ADevidence of neurodegeneration in a key memory and olfactory
processing area of the brainandmost importantlya significant decline in cognitive function over timeIn
order to fully explore the potential of this findinghere we seek to expand our participant pool by creating a
digital olfactory battery that couples with the POEM algorithmwith the ultimate goal that this can be self
administered independently at homeTo accomplish this goalwe have partnered with a leading digital health
companythe ADK groupto develop a mobile app and Scentovationsa company taking an innovative
approach to the design and manufacturing of odor delivery devices that are either reusable or disposableThe
mobile app will organize the subjectandapos s experience with instructions and cueswill collect the response data
generated in response to the testsand will send it securely to a central locationIn additionproprietary
naturalistic odors developed by International Flavors and Fragrances will be incorporated into this battery to
improve the perceptual salience of odors and performance across different cultures and continentsFollowing
the development of this prototypewe will seek to validate it in both a clinical and home settingUsed alone or
together with other non invasive measures that probe function of different brain regionsa remote test to
identify cognitively normal people harboring AD pathology and at risk of developing clinical AD is an essential
step to developing and clinically managing therapies that will impact the growing epidemic of AD Project Narrative
Detecting clinically normal elderly individuals with AD pathology and following their disease progression in a
non invasiveaffordable manner is a critical step to developing and monitoring disease modifying therapiesWe developed the POEMPercepts of Odor Episodic Memoryalgorithm to identify cognitively healthy elderly
individuals with neurodegeneration in their memory circuits and significant cognitive decline over timeTo seek
further validation of this promising methodologywe have teamed with a leading digital health company and
propose to develop a digital olfactory battery for remote assessment of the POEM algorithm using novel odor
diffusers and naturalistic odors
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Evaluate the Safety, Tolerability, and Immunogenicity of Adjuvanted Preventive Dual Aβ/tau Vaccine, Duvax in Healthy Volunteers
- A Drug Discovery Platform to Prioritize Development of Natural Product Neuromodulators for Treating Cognitive Impairment
- VR-CARES: Feasibility of Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support to improve social connection, health, and at-home dementia care
- Developing an Integrated Brain State Monitor for Personalized Anesthesia Decision Support: Preventing Postoperative Delirium in Elderly and Patients At Risk for Alzheimer's or Related Dementias
- Lead Optimization of a Therapeutic Candidate for Alzheimer’s Disease